🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Dr Martin Duddy updating MSTrust conference on the expected updates to MS diagnostic criteria #mstrustconference2025

Is clippers (chronic lymphocytes inflammation with continental perivascular enhancement responsive to steroids) paraneoplastic? Case series at #AAN2025

Timeline of development of therapies for neuromyelitis optica

For people switching from rituximab or ocrevus to tysabri for ms, the rate of relapses remained stable and had similar outcomes overall. #AANAM

The gemini I/II trials (tolebrutinib vs aubagio in relapsing ms) are now published! Tolebrutinib reduced disability progression modestly compared to aubagio but was not better in mri or relapse outcomes. #aanam nejm.org/doi/full/10.10…

Inebilizumab improves myasthenia gravis severity and reduces steroid dependency. Phase 3 trial shows significant improvement, with response magnitude increasing over time. Read more online! #AANAM25 Yale School of Medicine @AANMember hubs.la/Q03g7VGN0

Rituximab, a lower-cost treatment, may be as effective at managing RRMS as the approved therapy Ocrevus, a new study from Egypt suggests. bit.ly/4jDEQDV #news

A crossover trial showed that acetazolamide, furosemide, spironolactone, and topiramate significantly reduced intracranial pressure in IIH after 2 weeks—while amiloride showed no significant effect. Full results 👉 hubs.li/Q03h_FkD0

Issues reported: OPTIMAL Calculator for patients on Parkinson’s medication - converts oral Parkinson’s medications to Rotigotine patches, which may give inaccurate results. While a solution is found, please use PDMedCalc Calculator: pdmedcalc.co.uk A delay in

Find out why this was our most popular read this week:Migraine experts welcome the new ACP guideline on migraine prevention—but some recommendations are drawing concern. Join the conversation. @AANMember #NeuroTwitter hubs.ly/Q03l5vm90

Great to have #neuropharmacist representation at #ABN2025 again this year.

First speaker at #ABN2025 highlighting the current inequity in access to idebenone for Lebers Hereditary Optic Neuropathy across the UK. NICE are due to publish guidance on this in Sept 25

Interesting to see the experience of the Birmingham team of using tocilizimab in small case series of refractory status. Asking if the drug should be included in protocols #ABN2025

Fascinating to hear Prof Jacqueline Palace describe her amazing career at the ABN medalist lecture. From steroid sparing w azathioprone to compliment therapy #ABN2025

Talks this afternoon appraising new therapies. First up, an assesment of CGRP therapies by Prof Loder. Acknowledging the modest (underwhelming?) benefits of CGRPs and the newer PACAP molecules #ABN2025

Fantastic talk by Paresh Malhotra describing the history and current controversies around new treatments for Alzheimer’s. Lots of opportunities for pharmacists to support in the implementation of (if/when available!) Association of British Neurologists UKCPA Neurosciences Committee #ABN2025

Important to see this published: tinyurl.com/3skcvyn7. Through a UK wide collaboration (including Ruth Dobson Wallace Brownlee Ray Dorsey amongst others) we demonstrated discordance between the JCV testing available with biosimilar Natalizumab versus originator Natalizumab.

So excited to be teaching on the Neuropharmacist masterclass! An awesome opportunity as a previous delegate. Let’s go! Neurology Academy South Tees Hospitals Pharmacy Department

Today the most neuropharmacist in a room for a while. Learning together on Parkinson’s. Sharing information on device development projects and quality improvement across the nhs and involving neuropharmacists. So much has changed over the years Neurology Academy

We are kicking off the Neuropharmacy Masterclass hearing from Viv Horton & Dr Archibald about all things Parkinson’s Neurology Academy Neuropharmacists